Hormonal
A ketogenic diet (KD) improves glycemic control and insulin sensitivity in patients with Type 2 Diabetes Mellitus (T2DM) by reducing carbohydrate intake, lowering serum insulin, and enhancing fat catabolism.
For T2DM patients, adopting a ketogenic diet can significantly lower blood sugar and HbA1c levels compared to standard low-calorie diets. This is achieved by restricting carbohydrates, which lowers insulin levels and improves insulin sensitivity. However, medical supervision is critical, especially if you are taking insulin or SGLT2 inhibitors, to avoid dangerous side effects like hypoglycemia or ketoacidosis.
With the premise of ensuring constant total calorie intake, the KD reduces carbohydrate intake, lowers serum insulin levels, increases insulin sensitivity, and enhances fat catabolism, thus reducing blood lipids.
Why this rating
The paper cites multiple clinical studies, meta-analyses, and prospective studies showing significant HbA1c reduction and insulin sensitivity improvements.
Source
Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations
Huiyuan Zhu et al. · Signal Transduction and Targeted Therapy · 2022
DOI 10.1038/s41392-021-00831-w
More from this paper
- Ketone bodies (KBs) serve as an efficient energy source that bypasses glycolysis, promoting mitochondrial oxidative metabolism and reducing oxidative stress.Strong
- The Ketogenic Diet alters gut microbiota composition, increasing beneficial bacteria like Akkermansia and Parabacteriodes, which contributes to anti-seizure and anti-inflammatory effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →